EUCTR2008-008476-14-GB进行中（未招募）1 期
A Pharmacokinetic Study of Adjuvant Capecitabine in Patients who have undergone Proximal Pancreatico-Duodenectomy for Resection of Pancreatic Adenocarcinoma - Capecitabine PK Post Whipples (CAP001)
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Complete macroscopic resection for ductal adenocarcinoma of the pancreas (R0 or R1 resection).
- •Surgery must have included a proximal pancreatico-duodenectomy.
- •Histological confirmation of the primary diagnosis and examination of all resection margins
- •At least 4 weeks since surgery, fully recovered from the operation
- •Age = 18 years.
- •World Health Organisation (WHO) performance status of = 2
- •Haematological and biochemical indices (These measurements must be performed within one week prior to the patient being registered on the study.)
- •- Haemoglobin (Hb) = 9.0 g/dL (Patients may be transfused to this level, however, HB must be above 9.0 before registration)
- •- Neutrophils = 1.5 x 10^9/L
- •- Platelets (Plts) = 100 x 10^9/L
- •- Serum bilirubin = 1.5 x upper normal limit (ULN)
- •- Alanine amino-transferase (ALT) and / or aspartate amino-transferase (AST) = 2.5 x upper limit of normal (ULN). (If both are measured, both must be = 2.5 x ULN)
- •- Calculated creatinine clearance = 50 mL/min (uncorrected value) or isotope clearance measurement = 50 mL/min
- •Female patients of child-bearing potential must have a negative serum or urine pregnancy test within two weeks prior to enrolment and agree to use appropriate medically approved contraception for four weeks prior to entering the trial, during the trial, and for six months afterwards.
- •Male patients must agree to use appropriate medically approved contraception during the trial and for six months afterwards.
- •Written, informed consent provided.
- •Ability of the patient to co-operate with treatment and follow up must be ensured.
- •Patients receiving oral anti-coagulation prior to entry into the study, must be converted to low molecular weight heparin in light of the interaction between capecitabine and warfarin.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients with pancreatic lymphoma or other histological diagnosis
- •Macroscopically remaining tumour (R2 resection)
- •Evidence of malignant ascites, peritoneal or liver metastasis, or spread to other distant abdominal or extra-abdominal organs.
- •History of confirmed Ischaemic Heart Disease, concurrent congestive heart failure or prior history of class III / IV cardiac disease
- •Concurrent mechanical or malabsorptive disorders precluding affective oral administration of the drug (excluding malabsorption related directly to proximal pancreatic-duodenectomy)
- •Pregnancy or lactation
- •Patients known to be serologically positive for Hepatitis B, Hepatitis C or Human Immunodeficiency Virus (HIV).
- •Patients who are high medical risks because of non-malignant systemic disease including active uncontrolled infection.
- •Any other serious medical or psychological condition precluding adjuvant treatment
- •Patients with any other condition which in the Investigator’s opinion would not make the patient a good candidate for the clinical trial.
研究者
相似试验
已完成
1 期
Pharmacokinetic study of adjuvant capecitabine after resection of pancreatic adenocarcinomaCancerISRCTN88098646Cambridge University Hospitals NHS Foundation Trust (UK)12
已完成
4 期
Pharmacokinetic Study of Adjuvant Capecitabine After Resection of Pancreatic AdenocarcinomaPancreatic AdenocarcinomaNCT00854477Cambridge University Hospitals NHS Foundation Trust13
尚未招募
不适用
A study of pharmacokinetic analysis of capecitabine and cytidine deaminase activityBreast and colorectal cancerJPRN-UMIN000019244Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital20
招募中
4 期
Benefit of oral chemotherapy drug Capecitabine by comparing two different dose schedules with observation after standard treatment in triple negative Breast CancerCTRI/2024/05/066872Pt B D Sharma Postgraduate Institute of Medical Sciences
进行中（未招募）
1 期
A pharmacokinetic study of capecitabine in patients undergoing peri-operative chemotherapy and a total gastrectomy for adenocarcinoma of the stomach - Capecitabine PK Gastric (CAP002)Patients undergoing peri-operative chemotherapy and a total gastrectomy for adenocarcinoma of the stomachEUCTR2009-009908-39-GBCambridge University Hospitals NHS Foundation Trust13